New pill shows promise for Hard-to-Treat kidney cancer
NCT ID NCT05119335
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an oral drug called NKT2152 in people with advanced clear cell renal cell carcinoma that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The trial was terminated early, but the data may still help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NKT2152 (an oral HIF2α inhibitor)
What this could lead to
If successful, this could point toward a new oral treatment option for advanced kidney cancer that has stopped responding to other therapies.
What could go wrong
The trial was terminated early, so results are limited. It is still early-stage research, and the drug may not prove effective or safe in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
HonorHealth
Scottsdale, Arizona, 85258, United States
-
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
National Cancer Institute
Bethesda, Maryland, 20892-9760, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
UCLA
Los Angeles, California, 90095, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Oklahoma
Oklahoma City, Oklahoma, 73117, United States